Literature DB >> 1707469

Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines.

H Jernberg1, M Pettersson, T Kishimoto, K Nilsson.   

Abstract

The controversial role of interleukin-6 (IL-6) as an auto- or paracrine growth factor for human multiple myeloma (MM) cells was studied using a panel of six well characterized feeder-cell dependent and independent MM cell lines as models. With respect to the effect of IL-6 on growth and survival, three types of lines were found: (1) U-1958, dependent on IL-6 both for growth and survival; (2) U-1996, dependent on IL-6 for growth but not survival; and (3) U-266-1984, Fravel, L363, and Karpas 707, independent of IL-6. Feeder-cell supernatants were as efficient as feeder-cell monolayers in stimulating growth and contained IL-6 as the only growth promoting activity. IL-6 was growth stimulatory and sustained the growth of U-1958 only when the medium contained fetal calf serum. The nature of the serum factor(s) is unknown, but it was excluded to be the IL-6 carrier protein a2-macroglobulin. IL-1, IL-2, IL-3, TNF-alpha, GM-CSF, IGF-1, and insulin were neither co-stimulatory with IL-6 nor stimulated growth on their own. Only U-266-1984 expressed IL-6 mRNA. IL-6 receptor mRNA was expressed in all lines except the L363 and Fravel. We conclude that the response to IL-6 is heterogeneous among the MM lines and that IL-6 acts as a paracrine growth factor for two of six lines. In a third line, U-266-1984, the IL-6 mRNA expression suggests the possibility of an autocrine growth stimulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707469

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Cytokines involved in the progression of multiple myeloma.

Authors:  F Merico; L Bergui; M G Gregoretti; P Ghia; G Aimo; I J Lindley; F Caligaris-Cappio
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 2.  Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

Authors:  Michal Kuczma; Zhi-Chun Ding; Gang Zhou
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

3.  T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Authors:  D M Hilbert; M Y Shen; U R Rapp; S Rudikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

4.  In vitro culture of primary plasmacytomas requires stromal cell feeder layers.

Authors:  A Degrassi; D M Hilbert; S Rudikoff; A O Anderson; M Potter; H G Coon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

5.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

Authors:  M Schwabe; A T Brini; M C Bosco; F Rubboli; M Egawa; J Zhao; G L Princler; H F Kung
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

Review 6.  Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma.

Authors:  Helena Jernberg-Wiklund; Kenneth Nilsson
Journal:  Ups J Med Sci       Date:  2012-02-21       Impact factor: 2.384

7.  Myeloma: the role of interleukin 6.

Authors:  L Russell
Journal:  J R Soc Med       Date:  1993-08       Impact factor: 18.000

8.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Authors:  C Lu; R S Kerbel
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.